Adenocarcinoma of the prostate is the most common type of prostate cancer. It is caused by abnormal cell growth in the prostate gland. Risk factors for this cancer include age, race, family history, diet, and lifestyle.
Diagnosis of adenocarcinoma of the prostate is made through a combination of physical exam, laboratory testing, imaging tests, and biopsies. A digital rectal exam, urine test, and prostate-specific antigen (PSA) test may be used to help diagnose the cancer. Imaging tests such as ultrasound and CT scans may be used to view the prostate and surrounding tissues. A biopsy of the prostate will be needed to confirm the diagnosis.
Differential diagnosis for adenocarcinoma of the prostate includes benign prostatic hypertrophy (BPH), prostatitis, and other prostate cancers.
Treatment for adenocarcinoma of the prostate typically includes surgery, radiation therapy, and hormone therapy. Surgery may involve removing the entire prostate or removing just the tumor. Radiation therapy involves using high-energy X-rays to destroy cancer cells. Hormone therapy may be used to reduce the growth of cancer cells.
Prognosis for adenocarcinoma of the prostate depends on the stage of the cancer and the response to treatment. Early detection and treatment can lead to a better prognosis.